Chutes and Ladders

Latest Headlines

Latest Headlines

J&J boosts CEO pay to $25M, doubles R&D chief's haul

Johnson & Johnson CEO Alex Gorsky got a multimillion-dollar pat on the back for 2014. J&J's board upped his pay package to almost $25 million, with more cash, more options, and a much bigger chunk of J&J stock.

AstraZeneca adds hefty share grant to CEO's £3.5M pay

AstraZeneca CEO Pascal Soriot got a bit of a pay raise last year, with a 3% bump to his base salary. His bonus jumped, too, putting his salary, bonus and cash benefits at £3.5 million. But Soriot's real boost came in the form of equity that won't pay off for a few years: Some £4.8 million in shares, under the company's long-term incentive plan.

Christophe Weber is ready for the CEO job, Takeda says

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Merck dumps 120 Cubist researchers after its $9.5B merger

Merck has pulled the plug on Cubist Pharmaceuticals' early R&D operation, cutting 120 jobs in Massachusetts as it integrates its latest big acquisition.

Takeda's Weber must execute now that he is CEO

Japan's Takeda today officially named French national Christophe Weber its first non-Japanese CEO. The 49-year-old Weber, who takes over April 1, will now have to show whether he can succeed where so many other foreign heads of Japanese companies have not.

Frenchman Christophe Weber formally named CEO of Takeda, Japan's top and oldest drug company

Takeda Pharmaceutical officially announced on March 5 that President and Chief Operating Officer Christophe Weber would become chief executive officer staring April 1, replacing Yasuchika Hasegawa.

Mersana grabs a $35M round, posts ex-Millennium chief Protopapas at helm

For more than a year now, NEA general partner David Mott has helmed Mersana Therapeutics, a Cambridge, MA-based biotech that has been working on next-gen antibody-drug conjugates. But this morning he's handing the reins over to longtime biotech vet Anna Protopapas (while remaining chairman) after organizing a $35 million B round that will be announced later this morning.

Viehbacher joins PureTech board in first post-Sanofi venture

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry.

Brandicourt's departure piles on the exec shuffling at Bayer

With the hire of Bayer's Olivier Brandicourt as its new CEO, Sanofi will fill the hole it created when it ousted helmsman Chris Viehbacher nearly four months ago. But that means another leadership change is afoot at Brandicourt's current company, which is already in the middle of plenty of shuffling at the top.

Ariad activists strike up proxy fight to replace CEO Berger

Let the proxy fight begin. Activist hedge fund and major Ariad Pharmaceuticals shareholder Sarissa Capital has its own ideas for who it wants in the company's CEO chair--and it's not current helmsman Harvey Berger.